[144] Arcus Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Arcus Biosciences, Inc. (RCUS) notice reports a proposed sale of 1,579 common shares acquired under an Employee Stock Purchase Plan on 05/31/2025. The shares have an aggregate market value of $18,253.24 and the issuer has 106,430,976 shares outstanding. The sale is to be executed through Morgan Stanley Smith Barney LLC on the NYSE with an approximate sale date of 09/05/2025. Payment for the acquisition was cash. The filer states there were no securities sold by the person in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Full rule 144 disclosure of class, broker, acquisition date, acquisition source, consideration, and planned sale date is provided
• No sales in the past three months reported for the person, simplifying aggregation rules

Negative

• Filer identification details (CIK/contact) are not present in the provided content
• Position size is tiny relative to 106,430,976 outstanding shares, so the sale is not material

Insights

Securities Analyst

TL;DR Routine officer/insider plan sale of a small position acquired via ESPP; not material to company capitalization.

The filing documents a planned disposition of 1,579 common shares acquired under an Employee Stock Purchase Plan on 05/31/2025 with cash payment at acquisition. The planned sale is scheduled approximately three months later, on 09/05/2025, via Morgan Stanley Smith Barney LLC on the NYSE. The reported aggregate market value is $18,253.24 against 106,430,976 shares outstanding, indicating the position represents a de minimis fraction of outstanding equity. The notice also confirms no sales by the person during the prior three months and includes the required attestation regarding material nonpublic information.

Corporate Governance Expert

TL;DR Disclosure follows Rule 144 requirements for an ESPP sale notice; documentation appears complete for the information provided.

The form identifies the class, broker, acquisition date, acquisition source (Issuer via ESPP), consideration (cash), and anticipated sale date, which are the core Rule 144 disclosure items. The filer affirms the absence of material undisclosed information and indicates no aggregated sales in the prior three months. The filing does not include the filer CIK or contact details in the provided text, which are normally present elsewhere in the submission.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1579	18253.24	106430976	09/05/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/31/2025	Employee Stock Purchase Plan	Issuer			1579	05/31/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Arcus Biosciences (RCUS) disclose in this Form 144?

The filing discloses a proposed sale of 1,579 common shares acquired under an Employee Stock Purchase Plan on 05/31/2025, with an aggregate market value of $18,253.24, to be sold approximately on 09/05/2025 via Morgan Stanley Smith Barney LLC on the NYSE.

How were the shares to be sold acquired?

The shares were acquired from the issuer through an Employee Stock Purchase Plan on 05/31/2025, and payment was made in cash.

Does the filer report other sales in the prior three months?

The filing states Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

What broker and exchange are involved in the planned sale?

The broker listed is Morgan Stanley Smith Barney LLC, and the sale is to occur on the NYSE.

What attestation does the filer make regarding material information?

By signing, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed and notes the Rule 10b5-1 plan representation if applicable.